NCT00313079View on ClinicalTrials.gov

Monoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

February 28, 2009

Study Completion Date

July 31, 2009

Conditions
Leukemia, LymphocyticLeukemiaAcute Lymphocytic Leukemia
Interventions
DRUG

MAb 216

Dosage: 1.25mg/kg intravenous with dose escalation

DRUG

Vincristine

Dosage: 1.5mg/m2 intravenous weekly X 4

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

All Listed Sponsors
lead

Steven E. Coutre

OTHER

NCT00313079 - Monoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia | Biotech Hunter | Biotech Hunter